Healthcare, Pharma & Life Sciences

London – – October 08, 2026 -- The global cold plasma in healthcare market is projected to climb from $2,873 million in 2025 to $6,634 million by 2032, a compound annual growth rate of 12.7%, according to a new report from Credence Research Inc.

Devices dominate revenue while consumables build recurring streams

Devices accounted for 68.4% of product-segment revenue in 2025, reflecting continued emphasis on installed treatment capacity ahead of scaling consumables and service income. Plasma Jet technology held 39.6% of the technology segment, while Atmospheric Pressure Cold Plasma captured 66.8% of the pressure-type category, favored for bedside and outpatient use without vacuum infrastructure.

Johns Creek, Ga. – October 08, 2026 -- Boehringer Ingelheim has secured U.S. Food and Drug Administration approval for a new Quarterable Snap-Tab design of PREVICOX (firocoxib) Chewable Tablets, enabling veterinarians to prescribe the canine pain medication to dogs as small as seven pounds.

Double-scored tablets expand dosing precision for veterinarians

The redesigned 57 mg and 227 mg tablets feature double scoring that allows division into quarters, giving veterinarians more granular, weight-based dosing options for dogs across a broader size range. PREVICOX is a COX-2 selective NSAID approved for controlling pain and inflammation from osteoarthritis and for postoperative pain following soft-tissue and orthopedic surgery in dogs.

New York – October 07, 2026 -- Three early-career scientists each received $250,000 unrestricted prizes at the 2026 Blavatnik Awards for Young Scientists, the largest such award available to researchers under 42 in the United States.

Three laureates emerge from a pool of 372 nominees across 43 states

The Blavatnik Family Foundation and The New York Academy of Sciences selected the winners from 372 nominees representing 187 academic and research institutions. An independent jury also named 15 Finalists, each receiving $15,000 in unrestricted funding, plus nine Blavatnik Regional Awards honorees.

Pleasanton, Calif. – October 07, 2026 -- More than 175 emerging biotechs have adopted Veeva Basics, a suite of pre-configured, pre-validated applications spanning clinical, regulatory, quality, medical, and commercial functions, Veeva Systems (NYSE: VEEV) announced.

Biotechs deploy Veeva Basics applications in weeks instead of months

The pre-configured systems allow high-growth companies to move from startup to commercialization without building internal IT infrastructure or managing complex customizations. Whitehawk Therapeutics, a company with under 40 employees developing antibody-drug conjugates for difficult-to-treat cancers, used the platform to replace paper-based processes. "Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics.

Irvine, Calif. – October 07, 2026 -- MAXAIR Systems will supply a substantial quantity of its CAPR® helmet systems and related disposable equipment to World Vision for Ebola response efforts in the Democratic Republic of the Congo.

MAXAIR deepens 25-year partnership with World Vision on frontline protective gear

The Irvine, Calif.-based respiratory protection manufacturer confirmed the contribution is intended for healthcare professionals, humanitarian workers and other frontline teams operating in communities affected by the outbreak in the Democratic Republic of the Congo.

Rockville, Md. – October 07, 2026 -- The Agency for Healthcare Research and Quality (AHRQ) has launched a two-part, $7.95 million prize competition designed to compress medical evidence reviews that currently take a year or more down to a matter of hours using super intelligence systems.

Grand prize of $5.35 million targets evidence synthesis, the largest SI award issued to date

The Clinical Evidence Synthesis Transformation Challenge carries a $5.35 million grand prize, which AHRQ describes as the largest individual super intelligence grand prize awarded to date. Entrants will be judged on accuracy, throughput, reproducibility, usability and ease of operation. AHRQ Director Roger D. Klein, M.D., J.D., said the technology now allows evidence synthesis to be performed with speed, consistency and reproducibility that was previously unimaginable, a shift he said will help doctors, patients, payers and policymakers avoid unnecessary or harmful care.

Dallas – October 07, 2026 -- Patients who completed Annual Wellness Visits through Primary Partners Alliance's (PPA) population health strategy generated nearly $70 lower per-member-per-month healthcare costs than those who did not, according to a one-year analysis of the organization's Medicare Shared Savings Program and ACO REACH population.

AWV completion drove measurable cost and utilization reductions across PPA's network

The analysis found per-member-per-month costs of $947 for patients who completed an AWV versus $1,014 for those who did not. Readmission rates were 44% lower among AWV completers, at 9% compared with 16% for non-completers. Emergency department utilization also fell, registering 272 visits per 1,000 patients versus 286 per 1,000 for the comparison group.

Toronto – October 07, 2026 -- Vector Science and Therapeutics Corp. (TSXV: PAIN) has made an investment in Scoreboard, Inc., a performance wellness company co-founded by NBA Hall of Famer Gary Payton, through a Simple Agreement for Future Equity.

Vector and Scoreboard will co-develop peptide-based products for athletic performance, recovery and longevity

The two companies plan to jointly develop products using peptides formulated and manufactured by Vector, which tests all materials for purity, potency, endotoxin levels and sterility through validated analytical methods.

Doylestown, Pa. – October 07, 2026 -- Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will present new patient data for its LACRIFILL Canalicular Gel at the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, running October 9-12.

More than 2,200 U.S. practices now use LACRIFILL Canalicular Gel

The company reports that over 2,200 ophthalmology and optometry practices across the United States have adopted the gel for patients undergoing cataract or refractive surgery and for managing dry eye disease. More than 130,000 patients have been treated with the therapy to date.

Patient survey shows 96% report improved comfort after cataract surgery

In Nordic Pharma's latest patient experience survey, 96% of respondents who had cataract surgery within the past six months said LACRIFILL Canalicular Gel made their eyes feel better. Among all surveyed patients, 91% reported the same improvement.

Marlborough, Mass. – October 07, 2026 -- Boston Scientific Corporation (NYSE: BSX) has appointed Joseph M. Fitzgerald as executive vice president and chief operating officer, effective Jan. 1, 2027, a move paired with a restructuring of the company into three reportable business segments.

Boston Scientific splits operations into Interventional Therapies, Rhythm Solutions and MedSurg

The new segment structure takes effect Jan. 1, 2027. Interventional Therapies will combine the Interventional Cardiology, Vascular Therapies, and Interventional Oncology & Embolization businesses, and will absorb the Penumbra business once that acquisition closes. Rhythm Solutions will house Electrophysiology, WATCHMAN, and Cardiac Rhythm Management & Diagnostics. MedSurg will encompass Endoscopy, Urology and Neuromodulation.